An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases

Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively...

Descripción completa

Detalles Bibliográficos
Autores principales: Licari, Amelia, Castagnoli, Riccardo, Panfili, Elisa, Marseglia, Alessia, Brambilla, Ilaria, Marseglia, Gian Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735517/
https://www.ncbi.nlm.nih.gov/pubmed/29290750
http://dx.doi.org/10.2174/1573398X13666170616110738
_version_ 1783287222192046080
author Licari, Amelia
Castagnoli, Riccardo
Panfili, Elisa
Marseglia, Alessia
Brambilla, Ilaria
Marseglia, Gian Luigi
author_facet Licari, Amelia
Castagnoli, Riccardo
Panfili, Elisa
Marseglia, Alessia
Brambilla, Ilaria
Marseglia, Gian Luigi
author_sort Licari, Amelia
collection PubMed
description Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway. The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.
format Online
Article
Text
id pubmed-5735517
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-57355172017-12-29 An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases Licari, Amelia Castagnoli, Riccardo Panfili, Elisa Marseglia, Alessia Brambilla, Ilaria Marseglia, Gian Luigi Curr Respir Med Rev Article Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway. The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases. Bentham Science Publishers 2017-03 2017-03 /pmc/articles/PMC5735517/ /pubmed/29290750 http://dx.doi.org/10.2174/1573398X13666170616110738 Text en © 2017 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Licari, Amelia
Castagnoli, Riccardo
Panfili, Elisa
Marseglia, Alessia
Brambilla, Ilaria
Marseglia, Gian Luigi
An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
title An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
title_full An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
title_fullStr An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
title_full_unstemmed An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
title_short An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases
title_sort update on anti-ige therapy in pediatric respiratory diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735517/
https://www.ncbi.nlm.nih.gov/pubmed/29290750
http://dx.doi.org/10.2174/1573398X13666170616110738
work_keys_str_mv AT licariamelia anupdateonantiigetherapyinpediatricrespiratorydiseases
AT castagnoliriccardo anupdateonantiigetherapyinpediatricrespiratorydiseases
AT panfilielisa anupdateonantiigetherapyinpediatricrespiratorydiseases
AT marsegliaalessia anupdateonantiigetherapyinpediatricrespiratorydiseases
AT brambillailaria anupdateonantiigetherapyinpediatricrespiratorydiseases
AT marsegliagianluigi anupdateonantiigetherapyinpediatricrespiratorydiseases
AT licariamelia updateonantiigetherapyinpediatricrespiratorydiseases
AT castagnoliriccardo updateonantiigetherapyinpediatricrespiratorydiseases
AT panfilielisa updateonantiigetherapyinpediatricrespiratorydiseases
AT marsegliaalessia updateonantiigetherapyinpediatricrespiratorydiseases
AT brambillailaria updateonantiigetherapyinpediatricrespiratorydiseases
AT marsegliagianluigi updateonantiigetherapyinpediatricrespiratorydiseases

Ejemplares similares